Erlotinib Found To Be Marginally Cost-Effective In Economic Analysis
Links shared publicly online about this topic.
- 1,374total visits
Erlotinib Found To Be Marginally Cost-Effective In Economic Analysis
View full resource at medicalnewstoday.com
Tags: Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Drug, Tarceva
Most Recently Shared on February 17, 2010 at 10:09 pm By:
Erlotinib Found To Be Marginally Cost-Effective In Economic Analysis http://mnt.to/3xKp #clinicaltrials
Economic Analysis: Erlotinib Marginally Cost-Effective -- , 10.1093/jnci/djq023 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Economic Analysis: Erlotinib Marginally Cost-Effective -- , 10.1093/jnci/djq023 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on February 19, 2010 at 2:05 pm By:
H. Jack West, MD Internist, Health Executive, Oncologist, Physician, and Doctor
trying again: another link to economic analysis of BR.21 trial of Tarceva vs. placebo in advanced #lungcancer: http://bit.ly/9uMcpF
Economic Analysis: Erlotinib Marginally Cost-Effective -- , 10.1093/jnci/djq023 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Economic Analysis: Erlotinib Marginally Cost-Effective -- , 10.1093/jnci/djq023 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on February 19, 2010 at 6:26 am By:
H. Jack West, MD Internist, Health Executive, Oncologist, Physician, and Doctor
Analysis of cost-benefit for tarceva in #lung cancer, in J Nat'l Cancer Institute: http://bit.ly/bQgNL7
Economic analysis: Erlotinib marginally cost-effective
physorg.com — “Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial ...” View full resource at physorg.com
Most Recently Shared on February 16, 2010 at 11:44 pm By:
Economic analysis: Erlotinib marginally cost-effective http://bit.ly/d66TBP
Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer -- Bradbury et al., 10.1093/jnci/djp518 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer -- Bradbury et al., 10.1093/jnci/djp518 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on February 16, 2010 at 9:09 pm By:
J Nat'l Cancer Inst Medical Journal and Oncology
JNCI study---Economic Analysis: Erlotinib Marginally Cost-Effective http://bit.ly/bpnutE
Advertisement
